Technology offer : New Histone Deacetylase (HDAC) inhibitors as treatment for Toxoplasmosis and other parasitic diseases

Technology's description

Deacetylation of histones is required for gene regulation and cell cycle progression, the histone deacetylases, are being pursued as drug targets against parasitic diseases. However current HDAC inhibitors need to be used in high concentration to inhibit parasite growth and additionally most of HDAC inhibitors show little selectivity for intracellular stage of parasites compared to with their selectivity for human cells. Researchers have synthesizedand tested a family of new compound derived from hydroxybenzamide, and observed an HDAC inhibitory activity. In vitro activities of newly synthesized compounds on T.gondii proliferation were compared. Results show that one compound was presenting an inhibiting activity using less than 1ÁM and was the most selective to the intracellular proliferative stage of T.godii. Recently this compound has been successfully tested on the parasite Babesia.



Advantages

  • Activity proved on T.gondii and Babesia, and potential activity on other parasitic diseases
  • Low in-vitro toxicity
  • Anti T.gondii proliferation activity at less than 1ÁM
  • Human and animal health
Ref : OT-00024

Area of activity : HEALTH COSMETOLOGY

Download pdf

Industrial applications

  • Treatments against parasitic diseases, human and animal health.

Intellectual property

  • Patent field

Technology transfer

  • Co-development with licensing agreement

CONTACT


Vanessa ZEPPONI
Business developer

vanessa.zepponi@cvt-sud.fr
P: +33 (0)4 91 99 94 27